Stuyvesant Capital Management’s Pfizer PFE Stock Holding History

Stuyvesant Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$3.26M	Sell	78,755 -63,245	-45%	-$2.63M	7.93%	1
2018 Q3	$5.94M	Sell	142,000 -2,266	-2%	-$87.2K	11.39%	1
2018 Q2	$4.97M	Sell	144,266 -438	-0.3%	-$15K	9.25%	1
2018 Q1	$4.87M	Sell	144,704 -1,027	-0.7%	-$35.3K	9.93%	1
2017 Q4	$5.01M	Sell	145,731 -1,318	-0.9%	-$44.9K	9.06%	2
2017 Q3	$4.98M	Buy	147,049 +42,845	+41%	+$1.38M	10.13%	1
2017 Q2	$3.32M	Buy	104,204 +3,268	+3%	+$103K	6.55%	2
2017 Q1	$3.28M	Buy	100,936 +5,533	+6%	+$174K	6.91%	3
2016 Q4	$2.94M	Buy	95,403 +14,203	+17%	+$434K	6.33%	4
2016 Q3	$2.61M	Hold	81,200	–	–	6.06%	5
2016 Q2	$2.71M	Buy	81,200 +527	+0.7%	+$16.8K	5.36%	6
2016 Q1	$2.27M	Sell	80,673 -2,398	-3%	-$68.5K	5%	9
2015 Q4	$2.54M	Hold	83,071	–	–	6.4%	6
2015 Q3	$2.48M	Sell	83,071 -7,905	-9%	-$253K	6.25%	6
2015 Q2	$2.89M	Buy	90,976 +1,871	+2%	+$61K	6.31%	4
2015 Q1	$2.94M	Buy	+89,105	New	+$2.83M	6.7%	2

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stuyvesant Capital Management's PFE Position: Q4 2018 in Review

Stuyvesant Capital Management reduced its Pfizer (PFE) stake by 45% in Q4 2018, selling an estimated $2.63M and leaving 78,755 shares worth $3.26M. The position accounts for 7.93% of the portfolio, ranked #1.

Stuyvesant Capital Management first reported a position in PFE in Q1 2015 and has held it in 16 quarters since. The position peaked at $5.94M in Q3 2018. 2,403 funds tracked by Wall St. Rank hold PFE as of Q4 2018.

Stuyvesant Capital Management held 78,755 shares of Pfizer worth $3.26M as of Q4 2018.
Stuyvesant Capital Management sold 63,245 Pfizer shares in Q4 2018, an estimated $2.63M.
Pfizer made up 7.93% of Stuyvesant Capital Management's portfolio in Q4 2018, its #1 holding.
Stuyvesant Capital Management first reported a position in Pfizer in Q1 2015 and has held it in 16 quarters since.
Stuyvesant Capital Management's Pfizer position peaked at $5.94M in Q3 2018.
2,403 funds tracked by Wall St. Rank held Pfizer as of Q4 2018.

Based on Stuyvesant Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.